Trial · NCT04410445
Results by group26
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 26
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) of Bempegaldesleukin Plus Nivolumab Versus Nivolumab Alone | Bempegaldesleukin (NKTR-214) + Nivolumab | NA | 95% Confidence Interval 16.9 to NA | months | |
| Overall Survival (OS) of Bempegaldesleukin Plus Nivolumab Versus Nivolumab Alone | Nivolumab | NA | 95% Confidence Interval NA to NA | months | |
| Distant Metastasis-Free Survival (DMFS) by Investigator in Patients Who Are Stage III at Study Entry. | Bempegaldesleukin (NKTR-214) + Nivolumab | NA | 95% Confidence Interval NA to NA | months | |
| Distant Metastasis-Free Survival (DMFS) by Investigator in Patients Who Are Stage III at Study Entry. | Nivolumab | NA | 95% Confidence Interval NA to NA | months | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Bempegaldesleukin (NKTR-214) + Nivolumab | Patients who had a TEAE | 370 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Nivolumab | Patients who had a TEAE | 330 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Bempegaldesleukin (NKTR-214) + Nivolumab | Patients who had a Serious TEAE | 74 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Nivolumab | Patients who had a Serious TEAE | 33 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Bempegaldesleukin (NKTR-214) + Nivolumab | Patients who had a TEAE of Grade 3 or higher | 120 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Nivolumab | Patients who had a TEAE of Grade 3 or higher | 50 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Bempegaldesleukin (NKTR-214) + Nivolumab | Patients who had a TEAE Leading to Death | 1 | Participants | |
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Nivolumab | Patients who had a TEAE Leading to Death | 0 | Participants | |
Changes at 6 Months of Treatment From Baseline in Scores for the Global Health/Quality of Life (GH/QoL) and Physical Functioning Subscales of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire | Bempegaldesleukin (NKTR-214) + Nivolumab | Global Health Status/QoL at Baseline | 79.20 | Standard Deviation 16.284 | score on a scale |
Changes at 6 Months of Treatment From Baseline in Scores for the Global Health/Quality of Life (GH/QoL) and Physical Functioning Subscales of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire | Nivolumab | Global Health Status/QoL at Baseline | 79.83 | Standard Deviation 15.698 | score on a scale |
Changes at 6 Months of Treatment From Baseline in Scores for the Global Health/Quality of Life (GH/QoL) and Physical Functioning Subscales of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire | Bempegaldesleukin (NKTR-214) + Nivolumab | Global Health Status/QoL at 6 Months | 77.31 | Standard Deviation 17.342 | score on a scale |
Changes at 6 Months of Treatment From Baseline in Scores for the Global Health/Quality of Life (GH/QoL) and Physical Functioning Subscales of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire | Nivolumab | Global Health Status/QoL at 6 Months | 78.40 | Standard Deviation 16.776 | score on a scale |
Changes at 6 Months of Treatment From Baseline in Scores for the Global Health/Quality of Life (GH/QoL) and Physical Functioning Subscales of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire | Bempegaldesleukin (NKTR-214) + Nivolumab | Global Health Status/QoL Changes at 6 Months from Baseline | -3.71 | Standard Deviation 16.933 | score on a scale |
Changes at 6 Months of Treatment From Baseline in Scores for the Global Health/Quality of Life (GH/QoL) and Physical Functioning Subscales of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire | Nivolumab | Global Health Status/QoL Changes at 6 Months from Baseline | -1.48 | Standard Deviation 16.921 | score on a scale |
Changes at 6 Months of Treatment From Baseline in Scores for the Global Health/Quality of Life (GH/QoL) and Physical Functioning Subscales of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire | Bempegaldesleukin (NKTR-214) + Nivolumab | Physical Functioning Subscale at Baseline | 91.81 | Standard Deviation 13.159 | score on a scale |
Changes at 6 Months of Treatment From Baseline in Scores for the Global Health/Quality of Life (GH/QoL) and Physical Functioning Subscales of the European Organisation for Research and Treatment of Cancer Core Quality of Life Questionnaire | Nivolumab | Physical Functioning Subscale at Baseline | 91.96 | Standard Deviation 13.515 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04410445/results